🇪🇺 Intravitreal Injection in European Union

EMA authorised Intravitreal Injection on 13 February 2020

Marketing authorisation

EMA — authorised 13 February 2020

  • Application: EMEA/H/C/004913
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Beovu
  • Indication: Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
  • Status: approved

Read official source →

Other Ophthalmology approved in European Union

Frequently asked questions

Is Intravitreal Injection approved in European Union?

Yes. EMA authorised it on 13 February 2020.

Who is the marketing authorisation holder for Intravitreal Injection in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.